1. Home
  2. URG vs CTMX Comparison

URG vs CTMX Comparison

Compare URG & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ur Energy Inc (Canada)

URG

Ur Energy Inc (Canada)

HOLD

Current Price

$1.60

Market Cap

594.4M

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.70

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
URG
CTMX
Founded
2004
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
594.4M
596.2M
IPO Year
2006
2015

Fundamental Metrics

Financial Performance
Metric
URG
CTMX
Price
$1.60
$4.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$2.46
$8.86
AVG Volume (30 Days)
5.2M
2.2M
Earning Date
06-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$27,207,000.00
$138,103,000.00
Revenue This Year
$200.42
N/A
Revenue Next Year
$98.46
N/A
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
36.45
52 Week Low
$0.55
$0.40
52 Week High
$2.35
$6.35

Technical Indicators

Market Signals
Indicator
URG
CTMX
Relative Strength Index (RSI) 49.10 41.94
Support Level $1.47 $4.57
Resistance Level $1.62 $6.20
Average True Range (ATR) 0.11 0.33
MACD -0.00 -0.07
Stochastic Oscillator 52.53 8.82

Price Performance

Historical Comparison
URG
CTMX

About URG Ur Energy Inc (Canada)

Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: